Biovie is trading 10.45% down at $1.16, with its November 4 registered direct offering the clearest company-specific catalyst. - The offering covers 2,962,500 shares priced at $1.60 each, alongside warrants for up to the same number of shares. - Proceeds are intended for working capital and general corporate purposes. Biovie also fell 22.54% on November 4. - Broader market weakness may add pressure.